Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- DVYSR.ST
- Price
- 91.20
- Stock movement up
- +4.20 (4.83%)
- Company name
- Devyser Diagnostics AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Diagnostics & Research
- Market cap
- 1.51B
- Ent value
- 1.45B
- Price/Sales
- 7.60
- Price/Book
- 4.31
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 625.51
- PEG
- -
- EPS growth
- -
- 1 year return
- -14.37%
- 3 year return
- 6.76%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
DVYSR.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.60 |
| Price to Book | 4.31 |
| EV to Sales | 7.31 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 16.51M |
| EPS (TTM) | -4.33 |
| FCF per share (TTM) | -6.74 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 198.00M |
| Gross profit (TTM) | 160.70M |
| Operating income (TTM) | -76.90M |
| Net income (TTM) | -71.40M |
| EPS (TTM) | -4.33 |
| EPS (1y forward) | 0.15 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 81.16% |
| Operating margin (TTM) | -38.84% |
| Profit margin (TTM) | -36.06% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 171.40M |
| Net receivables | 49.50M |
| Total current assets | 258.90M |
| Goodwill | 6.80M |
| Intangible assets | 76.10M |
| Property, plant and equipment | 0.00 |
| Total assets | 462.90M |
| Accounts payable | 10.10M |
| Short/Current long term debt | 61.20M |
| Total current liabilities | 61.50M |
| Total liabilities | 113.90M |
| Shareholder's equity | 349.00M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -59.10M |
| Capital expenditures (TTM) | 52.00M |
| Free cash flow (TTM) | -111.10M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -20.46% |
| Return on Assets | -15.42% |
| Return on Invested Capital | -19.69% |
| Cash Return on Invested Capital | -30.63% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 88.40 |
| Daily high | 91.40 |
| Daily low | 88.00 |
| Daily Volume | 32K |
| All-time high | 140.00 |
| 1y analyst estimate | 158.42 |
| Beta | 0.74 |
| EPS (TTM) | -4.33 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2025 |
Downside potential
Loading...
Downside potential data
| DVYSR.ST | S&P500 | |
| Current price drop from All-time high | -34.86% | -12.04% |
| Highest price drop | -40.94% | -56.47% |
| Date of highest drop | 8 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -18.44% | -11.07% |
| Avg time to new high | 25 days | 12 days |
| Max time to new high | 534 days | 1805 days |
COMPANY DETAILS
Marketcap
1.51B
Marketcap category
Small-cap
Description
Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is headquartered in Hägersten, Sweden.
Employees
119
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found